DS
Therapeutic Areas
Agios Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Pyrukynd (mitapivat) | Hemolytic anemia in adults with Pyruvate Kinase (PK) Deficiency | Approved |
| Mitapivat | Non-Transfusion-Dependent Thalassemia | Phase 3 |
| AG-946 | Hemolytic Anemias and other indications | Phase 1 |
Leadership Team at Agios Pharmaceuticals
BG
Brian Goff
Chief Executive Officer
CJ
Cecilia Jones
Chief Financial Officer
SG
Sarah Gheuens, M.D., Ph.D.
Chief Medical Officer, Head of R&D
TM
Tsveta Milanova
Chief Commercial Officer
KV
Krishnan Viswanadhan, Pharm.D.
Chief Corporate Development and Strategy Officer
JB
Jim Burns
Chief Legal Officer
CP
Clive Patience, Ph.D.
Chief Technical Operations Officer
EL
Ellen Lopresti
Chief People Officer
RB
Rahul Ballal, Ph.D.
Board of Directors
JC
Jeffrey Capello
Board of Directors